Ticker
ADCT

Price
7.33
Stock movement down
-0.30 (-3.93%)
Company name
Adc Therapeutics SA
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
563.02M
Ent verdi
551.37M
Pris/omsetning
7.00
Pris/bok
3.46
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
-71.66%
3 års avkastning
-
5 års avkastning
-
10 års avkastning
-
Sist oppdatert: 2022-08-25

UTBYTTE

ADCT betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning7.00
Pris til bok3.46
EV i forhold til salg6.86

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall76.81M
EPS (TTM)-2.54
FCF per aksje (TTM)-2.85

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)80.42M
Bruttofortjeneste (TTM)78.49M
Driftsinntekter (TTM)-231.42M
Netto inntekt (TTM)-195.16M
EPS (TTM)-2.54
EPS (1 år fremover)-3.23

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)97.61%
Driftsmargin (TTM)-287.78%
Fortjenestemargin (TTM)-242.69%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter430.87M
Netto fordringer26.75M
Samlede omløpsmidler487.71M
Goodwill0.00
Immaterielle eiendeler13.85M
Eiendom, anlegg og utstyr0.00
Sum eiendeler581.89M
Leverandørgjeld16.45M
Kortsiktig/nåværende langsiktig gjeld0.00
Sum kortsiktig gjeld70.77M
Sum gjeld419.22M
Aksjonærenes egenkapital162.67M
Netto varige driftsmidler149.53M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-212.11M
Kapitalutgifter (TTM)6.72M
Fri kontantstrøm (TTM)-218.84M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-119.98%
Avkastning på eiendeler-33.54%
Avkastning på investert kapital-71.44%
Kontantavkastning på investert kapital-80.11%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning7.72
Daglig høy7.78
Daglig lav7.11
Daglig volum101K
Tidenes høyeste51.05
1 år analytikerestimat27.50
Beta1.29
EPS (TTM)-2.54
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon-

Nedsidepotensial

Loading...
Nedsidepotensial-data
ADCTS&P500
Nåværende prisfall fra toppnotering-85.64%-12.18%
Høyeste prisfall-88.33%-56.47%
Dato for høyeste fall16 Jun 20229 Mar 2009
Gj.snittlig fall fra topp-49.74%-11.38%
Gj.snittlig tid til ny topp36 days12 days
Maks tid til ny topp542 days1805 days
SELSKAPSOPPLYSNINGER
ADCT (Adc Therapeutics SA) company logo
Markedsverdi
563.02M
Markedsverdi kategori
Small-cap
Beskrivelse
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Ansatte
312
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Land
USA
By
Aksjetype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
LAUSANNE, Switzerland, September 21, 2022--ADC Therapeutics SA (NYSE: ADCT) today announced that ZYNLONTA® (loncastuximab tesirine-lpyl) and camidanlumab tesirine (Cami) abstracts have been accepted f...
21. september 2022
LAUSANNE, Switzerland, September 16, 2022--ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi®) today announced the Committee for Medicinal Products for Human Use (CHMP) of the Eur...
16. september 2022
LAUSANNE, Switzerland, September 06, 2022--ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley’s 20th Ann...
6. september 2022
LAUSANNE, Switzerland, August 15, 2022--ADC Therapeutics SA (NYSE: ADCT) today announced that it has completed a series of strategic transactions in which it:
15. august 2022
On today's call, Ameet Mallik, chief executive officer; Jennifer Herron, chief commercial officer; Joe Camardo, chief medical officer; and Jenn Creel, chief financial officer, will discuss recent busi...
10. august 2022
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 23.96% and 14.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
9. august 2022
LAUSANNE, Switzerland, August 09, 2022--ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2022 and provided business updates.
9. august 2022
Intercept (ICPT) delivered earnings and revenue surprises of -28.30% and +5.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
5. august 2022
Intercept (ICPT) delivered earnings and revenue surprises of -28.30% and 24.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
3. august 2022
LAUSANNE, Switzerland, August 02, 2022--ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 9, 2022 at 8:30 a.m. ET to report finan...
2. august 2022
Neste side